Display options
Cite
Doucette K, DeStefano CB, Jain NA, et al. Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG). Res Pract Thromb Haemost. 2017;1(1):134-137doi: 10.1002/rth2.12009.
Doucette, K., DeStefano, C. B., Jain, N. A., Cruz, A. L., Malkovska, V., & Fitzpatrick, K. (2017). Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG). Research and practice in thrombosis and haemostasis, 1(1), 134-137. https://doi.org/10.1002/rth2.12009
Doucette, Kimberley, et al. "Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG)." Research and practice in thrombosis and haemostasis vol. 1,1 (2017): 134-137. doi: https://doi.org/10.1002/rth2.12009
Doucette K, DeStefano CB, Jain NA, Cruz AL, Malkovska V, Fitzpatrick K. Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG). Res Pract Thromb Haemost. 2017 Jun 19;1(1):134-137. doi: 10.1002/rth2.12009. eCollection 2017 Jul. PMID: 30046682; PMCID: PMC6058197.
Copy Download .nbib Format: NLM
Share it on

Res Pract Thromb Haemost. 2017 Jun 19;1(1):134-137. doi: 10.1002/rth2.12009. eCollection 2017 Jul.

Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG).

Research and practice in thrombosis and haemostasis

Kimberley Doucette, Christin B DeStefano, Natasha A Jain, Allan L Cruz, Vera Malkovska, Kelly Fitzpatrick

Affiliations

  1. Department of Internal Medicine Medstar Washington Hospital Center Washington DC USA.
  2. Department of Hematology/Oncology Medstar Washington Hospital Center Washington DC USA.

PMID: 30046682 PMCID: PMC6058197 DOI: 10.1002/rth2.12009

Abstract

Delayed onset heparin induced thrombocytopenia (HIT), is characterized by a late nadir due to persistent platelet-activating IgG antibodies. It typically begins or worsens 5 or more days after heparin is discontinued with complications such as thrombosis up to 3 weeks after exposure to heparin.

Keywords: heparin; immunoglobulins, intravenous; thrombocytopenia; thrombosis

References

  1. Chest. 2017 Sep;152(3):478-485 - PubMed
  2. Am J Hematol. 2015 Jul;90(7):675-8 - PubMed
  3. J Thromb Haemost. 2009 Jul;7 Suppl 1:9-12 - PubMed
  4. Thromb Haemost. 1994 May;71(5):641-5 - PubMed
  5. Blood. 2010 Mar 4;115(9):1797-803 - PubMed
  6. J Clin Immunol. 1998 Sep;18(5):330-4 - PubMed
  7. Blood. 2014 Apr 17;123(16):2485-93 - PubMed
  8. Am J Hematol. 1992 Apr;39(4):312-3 - PubMed
  9. Br J Haematol. 2003 May;121(4):535-55 - PubMed
  10. Curr Opin Hematol. 2016 Sep;23(5):462-70 - PubMed
  11. J Thromb Haemost. 2011 Dec;9(12):2389-96 - PubMed
  12. J Thromb Haemost. 2008 Mar;6(3):428-35 - PubMed
  13. CMAJ. 2014 Sep 2;186(12):929-33 - PubMed
  14. Circulation. 1999 May 18;99(19):2530-6 - PubMed
  15. Ann Intern Med. 2001 Oct 2;135(7):502-6 - PubMed
  16. Transfusion. 2017 Apr;57(4):919-923 - PubMed
  17. Am J Med. 1996 Nov;101(5):502-7 - PubMed
  18. Ann Intern Med. 2002 Feb 5;136(3):210-5 - PubMed
  19. Ann Intern Med. 1989 Dec 1;111(11):946-7 - PubMed

Publication Types